Briefs: Shilpa Medicare and Medico Remedies

Medico Remedies receives order worth US$ 1,781,000

PromoCell launches custom GMP cell culture media to power next-gen cell and gene therapies

New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain

India invites applications under PRIP scheme to drive pharma-medtech innovation

Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance

Gleneagles Hospital Mumbai and Medtronic host conclave on hub & spoke model and AI in healthcare

The Hub & Spoke model is designed to extend advanced medical care to a wider community

AstraZeneca to launch DTC medication platform, offering up to 70% discounts on Farxiga, Airsupra

The platform is being introduced to expand access to treatments for people living with chronic conditions

Lunit and Agilent collaborate to develop AI-powered diagnostic solutions for precision medicine

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities

Shilpa Medicare receives initial authorization for Rivaroxaban Orodispersible films from EMA

Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1

The facility has been classified as Voluntary Action Indicated

Poly Medicure acquires Italy’s Citieffe Group for Rs. 324 Cr

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada